SynthesisTargeted oncology2016

Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.

Gaetan Des Guetz et al.PubMed ↗Publisher ↗

No numbers read from the abstract.